US Stock Market Move | U.S. clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuted on the U.S. stock market, with its share price falling more than 10% after the opening bell.

On Friday, Retension Pharmaceuticals (RTSN.US) debuted on the U.S. stock market. As of press time, the stock fell more than 10%, trading at $10.77. The IPO price was $12. Retension Pharmaceuticals is a U.S. clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a next-generation phosphodiesterase 5 (PDE5) inhibitor primarily targeting patients with inadequately controlled blood pressure and resistant hypertension, and is currently undergoing Phase IIb clinical trials. The drug helps dilate blood vessels and lower blood pressure by enhancing nitric oxide signaling in blood vessels, and its exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).